With the approval of Belimumab, as a therapeutic anti‐BAFF monoclonal antibody for treating autoimmune diseases, additional studies that analyze the interplay of BAFF and EBV could identify novel approaches to treating EBV‐associated diseases. The gene discussed is TNFSF13B; the disease is autoimmune disease.